A Flow of New Options for Relapsed and Refractory Hodgkin Lymphoma
Can a new antibody drug conjugate, ADCETRIS (brentuximab vedotin), be the foundation of new combination therapies for patients with relapsed or refractory... Learn More
Day
October 13, 2012